| Name | Title | Contact Details |
|---|
Agiliti is a company of 3,000 passionate equipment management experts who believe every interaction has the power to change a life. We have built a brand thats dedicated to optimizing clinical outcomes while relentlessly improving economic outcomes for our customers. We help hospitals and health systems address their challenges — including compliance requirements, general cost pressures, the rise of consumerism, looming talent shortages and the rising quality issues related to medical devices. We ensure the right equipment is in the right place at the right time — from infusion pumps to beds to imaging devices — so physicians, nurses and other caregivers spend more time focused on patient care. We provide supply chain teams with valuable insights they can use to control costs. And we offer a full range of clinical engineering services — supplemental support and full outsource programs — to unburden your biomed department.
Alliant Health Solutions is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Pip is an app that helps people prepare for and recover from surgery, providing access to 1:1 care, resources, and checklists at every stage of surgery.
Feinstein Kean Healthcare is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Cambridge, MA. To find more information about Feinstein Kean Healthcare, please visit www.fkhealth.com
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.